期刊文献+

盖诺与顺铂联合化疗加同期放射对乳腺癌MCF-7细胞作用的研究 被引量:1

Study of NVB and DDP chemotherapy with concurrent radiotherapy on breast cancer MCF-7 cells
下载PDF
导出
摘要 目的:探讨盖诺(NVB)联合顺铂(DDP)的放化同期治疗乳腺癌的有效性、时机选择和作用机制。方法:NVB和DDP(NP方案)对乳腺癌MCF-7细胞联合化疗同期放射。比较照射加联合化疗组和单纯照射组、不同间隔时间联合化放疗的细胞存活率(SF)、凋亡和细胞周期阻滞差异。结果:联合化疗加同期放射后SF较单独放疗更低。化疗处理后间隔4、12和36h照射的SF值最低,0h居中,而间隔48和72h后,SF值明显上升,放化疗协同杀灭效应减弱,SF最低与最高值相差约15倍。联合化疗加照射组细胞凋亡指数(AI)明显高于单独放射和联合化疗组。6、8Gy放射后36h时,放化疗联合组与单独放射组比较AI分别高达30.7%、38.35%和2.22%、3.27%,差异有统计学意义,P<0.05。化疗处理MCF-7细胞1h后在间隔4、12、36和72h处,G2/M周期细胞比例较高,0、48h处较低。结论:联合化放疗对乳腺癌MCF-7细胞具有较强的协同杀灭作用,化放联合治疗的时机选择在肿瘤细胞杀灭过程中具有重要的意义,这种协同杀灭作用与增加细胞凋亡率和化疗造成的细胞G2/M周期阻滞有关。 OBJECTIVE: To explore the effectivity of concur-rent radiotherapy and chemotherapy, opportunity chosing and mecha-nism on breast cancer MCF-7 cells. METHODS: The results of sur- vival fractions (SF) among the groups of combination of NVB and DDP with concurrent radiotherapy, chemotherapy and radiotherapy alone were compared. Further researches on apoptosis, cell cycle ac-cumulation within these groups were done. RESULTS: SF of the group combined chemotherapy with radiation was much lower than that of group of radiotherapy alone. The SFs of MCF-7 cells irradia- ted at 4 h, 12 h and 36 h after the chemotherapy were the lowest. SF at 0 h was middling. SFs at 48 h and 72 h after the chemotherapy were found rising greatly. The highest SF was about 15 times of the lowest. Apoptosis index (AI) of the combination group of chemo-therapy and radiation was much higher than those of groups of chem- otherapy and radiation alone. Especially at 36 h after 6 Gy or 8 Gy by being irradiated, AIs of the combination group of chemotherapy and radiation were 30.7% and 38. 350/60 while AIs of group of radiation a-lone were 2.22% and 3.27%, P〈0.05. G2/Ms of MCF-7 cell at 4, 12, 36 and 72 hours after chemotherapy were higher compared with those at 0 and 48 hours later. CONCLUSIONS: Teh combination of concurrent chemotherapy with radiotherapy can make much stronger cooperated killing action on MCF-7 cells, Opportunity of the combi-nation treatment takes a great significance during this process, This kind of cooperated killing is related to the increase of apoptosis from combination of chemotherapy with radiation and cell cycle accumula-tion at G2/M caused by chemotherapy.
出处 《中华肿瘤防治杂志》 CAS 2007年第17期1298-1301,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 云南省卫生厅课题资助(99M126)
关键词 乳腺肿瘤 治疗 放射疗法 药物疗法 联合 综合疗法 肿瘤细胞 培养的 凋亡 细胞周期 breast neoplasms therapy radiotherapy drug therapy, combinations tumor cells, cultured apoptosis cell cycle
  • 相关文献

参考文献8

  • 1Isaac N,Panzarella T,Lau A,et al.Concurrent cyclophosphamide,methotrexate,and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma:a well tolerated adjuvant regimen[J].Cancer,2002,95(4):696-703.
  • 2Faul C,Brufsky A,Gerszten K,et al.Concurrent sequencing of full-dose CMF chemotherapy and radiation therapy in early breast cancer has no effect on treatment delivery[J].Eur J Cancer,2003,39(6):763-768.
  • 3Kao J,Conzen S D,Jaskowiak N T,et al.Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer:results from two consecutive phase Ⅰ/Ⅱ trials[J].Int J Radiat Oncol Biol Phys,2005,61(4):1045-1053.
  • 4梁莉,张淑兰,张照辉,王俊杰,贾廷珍.联合放、化疗与单一化疗对乳腺癌患者心电图的影响[J].中华放射医学与防护杂志,2005,25(3):262-264. 被引量:5
  • 5Chakravarthy A B,Kelley M C,McLaren B,et al.Neoadjuvant concurrent paclitaxel and radiation in stage Ⅱ/Ⅲ breast cancer[J].Clin Cancer Res,2006,12(5):1570-1576.
  • 6Burstein H J,Bellon J R,Galper S,et al.Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage Ⅱ or Ⅲ breast cancer[J].Int J Radiat Oncol Biol Phys,2006,64(2):496-504.
  • 7Bollet M A,Sigal-Zafrani B,Gambotti L,et al.Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer:Results of a phase Ⅱ study[J].Eur J Cancer,2006,42(14):2286-2295.
  • 8张盛奇,丘希辉,庄晓文,杨钰贤,江艺,陈志明,林丹霞.长春瑞滨联合顺铂治疗转移性乳腺癌40例疗效观察[J].肿瘤防治杂志,2005,12(15):1174-1175. 被引量:1

二级参考文献16

  • 1Smith G A.Current status of vinorelbine for breast cancer[J]. Oncology (Huntingt), 1995,9(8):767-773; discussion 774, 776, 779.
  • 2Mustacchi G, Muggia M, Milani S, et al. A phaseⅡ study of cisplatin and Vinorelbine in patients with metastatic breast cancer[J]. Ann Oncol,2002, 13(11):1730-1736.
  • 3Vassilomanolakis M, Koumakis G, Demiri M, et al. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in platients progressing after docetaxel and anthracycline treatment[J]. Cancer Invest, 2003,21(4):497-504.
  • 4Miller A B, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment[J].Cancer, 1981, 47(1): 207-214.
  • 5潘启超.新抗癌药物的进展[A].曹世龙.肿瘤学新理论与新技术[C].上海:上海科技教育出版社,1997.407-436.
  • 6Decatris M P, Sundar S, O'Byrne K J. Platinum-based chemotherapy in metastatic breast cancer: current status[J]. Cancer Treat Rev,2004, 30(1):53-81.
  • 7Iaffaioli R V, Tortoriello A, Facchini G, et al. A phaseⅡ study of carboplatin and Vinorelbine as second-line treatment for advanced breast cancer[J]. Br J Cancer,1995,72(5),1256-1258.
  • 8Basavaraju SR, Easterly CE. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med Phys, 2002, 29:2391-2403.
  • 9Lacko A, Wlodarska I, Zymlinski R, et al. Cardiac toxicity in cancer therapy. Pol Merkuriusz Lek, 2002, 13:79-85.
  • 10Ryberg M, Nielsen D, Skovsgaard T, et al. Epirubicin cardiotoxicity:an analysis of 469 patients with metastatic breast cancer. J Clin Oncol,1998, 16:3502-3508.

共引文献4

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部